Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2012. The report details an update regarding GSK's ongoing tender offer to acquire Human Genome Sciences (HGS). GSK is a leading research-based pharmaceutical and healthcare company.
Key Financial Metrics and Transaction Details
- Offer Price: US$13.00 per share in cash for all outstanding HGS shares.
- Premium: Represents an 81% premium to HGS's closing share price of US$7.17 on April 18, 2012.
- Tendered Shares: As of the close of business on June 28, 2012, approximately 375,526 shares had been tendered and not withdrawn.
- Expected Synergies: GSK anticipates cost synergies of at least US$200 million from the combination.
- Strategic Assets: The offer reflects the value of Benlysta, darapladib, albiglutide, and HGS's operating and financial assets.
Material Changes and Updates
The primary material change reported is the extension of the tender offer expiration date. The offer, previously scheduled to expire on June 29, 2012, has been extended to 5:00 p.m. New York City time on July 20, 2012. This extension allows HGS shareholders to evaluate the outcome of HGS's strategic alternatives review process, which has a definitive proposal deadline of July 16, 2012. All other terms and conditions of the offer remain unchanged.
Outlook, Risks, and Management Commentary
GSK management believes the three-month duration of the strategic review process is adequate for completion. The company remains willing to meet and review its offer with HGS at any time but noted it can make no assurance that the tender offer will be further extended beyond July 20. The offer is not conditioned on due diligence or financing. GSK highlighted its unique positioning due to a near 20-year relationship with HGS and existing ownership stakes in key assets like Benlysta. The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties.
Investor Verification Checklist
- Verify the final number of shares tendered by the July 20, 2012, expiration deadline.
- Monitor the outcome of HGS's strategic alternatives review process concluding on July 16, 2012.
- Review the amended tender offer documents filed on Schedule TO with the SEC on May 10 and May 23 for full terms and conditions.
- Confirm whether GSK will extend the offer further or withdraw it based on the July 20 outcome.